Physician profile
Steve B Park
NPI 1053393009
$12,969.69
in general payments reported to CMS, 2019-2025
24 companies · $1,692 in 2025
The $1,692 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,907 · 2020: $1,315 · 2021: $1,389 · 2022: $1,206 · 2023: $1,654 · 2024: $1,807 · 2025: $1,692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,153.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,823.58 | 2019-2025 | Clareon, Centurion, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $2,369.99 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Sight Sciences, INC. | $1,817.96 | 2019-2024 | Omni Surgical System |
| Abbvie INC. | $928.84 | 2022-2025 | |
| Glaukos Corporation | $818.04 | 2020-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idose, Istent Infinite |
| Allergan, INC. | $488.76 | 2019-2022 | |
| Ivantis, INC | $366.61 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $340.82 | 2019-2025 | |
| Tarsus Pharmaceuticals, INC. | $284.51 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $251.91 | 2022-2024 | Miebo, Xiidra |
| Biotissue Holdings INC. | $246.09 | 2021-2025 | |
| Aerie Pharmaceuticals, INC. | $222.93 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $122.98 | 2019 | |
| Oyster Point Pharma, INC. | $115.68 | 2022-2025 | Tyrvaya, Ryzumvi |
| Shire North American Group INC | $115.31 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $115.00 | 2023 | |
| Amgen INC. | $111.17 | 2024 | Uplizna |
| Kala Pharmaceuticals, INC. | $101.81 | 2021 | |
| Rxsight INC | $77.78 | 2024 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Thea Pharma INC. | $70.50 | 2023-2024 | Iyuzeh |
| Dompe US, INC. | $65.96 | 2021-2025 | Oxervate |
| Ocular Therapeutix, INC. | $59.51 | 2025 | Dextenza |
| Novartis Pharmaceuticals Corporation | $31.95 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $22.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.